FIG 11.

The loss of VCP inhibits RVFV virion egress to a level comparable to that achieved with sorafenib treatment. (A and B) Huh7 cells were treated with either negative-control siRNA or siRNA targeting VCP, followed by infection with MP12 at an MOI of 0.1 for 24 h. (A) The intra- and extracellular infectivity per infection, as determined by plaque assay, is plotted. (B) Total infectivity (i.e., the sum of intra- and extracellular infectivity) per infection was determined. The percentage of intracellular infectivity relative to the total infectivity was plotted for siNeg- and siVCP-transfected cells. (C and D) Vero cells were treated with either DMSO or sorafenib, followed by infection with MP12 at an MOI of 0.1 for 24 h. Intracellular versus extracellular infectivity (C) and the percentage of intracellular infectivity (D) were plotted as mentioned above. The means and standard deviations from three biological replicates are plotted. *, P < 0.05.